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Abstract The most common cause of amyotrophic lateral
sclerosis (ALS) is mutations in superoxide dismutase-1
(SOD1). Since there is evidence for the involvement of
non-neuronal cells in ALS, we searched for signs of SOD1
abnormalities focusing on glia. Spinal cords from nine ALS
patients carrying SOD1 mutations, 51 patients with spo-
radic or familial ALS who lacked such mutations, and 46
controls were examined by immunohistochemistry. A set
of anti-peptide antibodies with speciﬁcity for misfolded
SOD1 species was used. Misfolded SOD1 in the form of
granular aggregates was regularly detected in the nuclei of
ventral horn astrocytes, microglia, and oligodendrocytes in
ALS patients carrying or lacking SOD1 mutations. There
was negligible staining in neurodegenerative and non-
neurological controls. Misfolded SOD1 appeared occa-
sionally also in nuclei of motoneurons of ALS patients. The
results suggest that misfolded SOD1 present in glial and
motoneuron nuclei may generally be involved in ALS
pathogenesis.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disease mainly characterized by progressive loss of upper
and lower motoneurons and death usually ensues within
3–5 years after diagnosis. More than 150 mutations in the
ubiquitously expressed enzyme superoxide dismutase-1
(SOD1) have been associated with familial ALS (FALS)
and such mutations are found in about 6% of all ALS
patients [35, 45]( http://alsod.iop.kcl.ac.uk). The mutations
confer a cytotoxic property on the enzyme that is poorly
understood [16]. Nine of the mutations cause long C-ter-
minal truncations. These mutant SOD1s lack the stabilizing
C57-C146 intrasubunit disulﬁde bond and also strand 8 in
the b-barrel core of the protein, and thus cannot adopt
native folding. The most extensively studied truncation
mutant, Gly127insTGGG (G127X), has been found to be
rapidly degraded and to be present only in minute amounts
in the human spinal cord [22]. The mutant SOD1s associ-
ated with ALS should most likely cause ALS by essentially
the same mechanism. This implies that any common
cytotoxic conformational species of SOD1 should be mis-
folded and present in minute amounts in the tissue.
The wild-type human SOD1 can also have neurotoxic
effects. Transgenic overexpression in mice leads to axonal
abnormalities and a late moderate loss of ventral horn
neurons [19, 24], and it exacerbates disease caused by
mutant SOD1s [11, 19]. Compared to D90A, the most
common of the ALS-associated mutant SOD1s, wild-type
human SOD1 is between half and equally neurotoxic in
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DOI 10.1007/s00401-011-0805-3mice [23]. Damage to this long-lived protein causes
destabilization and results in interaction properties and
toxicity similar to those found for mutant SOD1s [5, 34].
There is considerable evidence for the involvement of
non-neuronal cells in the pathogenesis of ALS. In murine
SOD1 models, down-regulation of SOD1 expression in
astrocytes [47] and microglia [2] slows progression after
disease onset, whereas down-regulation in motoneurons
delays onset [4, 47]. In chimeric mice, motoneurons
expressing mutant SOD1s are spared if surrounded by non-
transgenic glial cells [10]. Neuron-restricted synthesis of
G93A mutant SOD1 in mice is, however, sufﬁcient to
cause motoneuron pathology and a late ALS-like disease
[20, 43]. Mutant SOD1 expression in oligodendrocytes
might protect against loss of motoneurons [46]. The exact
role of non-neuronal cells in the pathogenesis of human
ALS is unknown, but all cells implicated in the transgenic
models show signs of activation or alterations.
We have developed a set of antibodies which allow
speciﬁc detection of misfolded SOD1 against the abundant
background of native enzyme in the human CNS. Using
these antibodies, we have previously shown that inclusions
containing misfolded SOD1 are regularly present in moto-
neuron somas of ALS patients, both with and without SOD1
mutations [12]. The ﬁnding of misfolded SOD1 in sporadic
ALS (SALS) was recently conﬁrmed by Bosco et al. [5],
and they also found that wild-type SOD1 immunopuriﬁed
from SALS tissues inhibited fast axonal transport in a
manner similar to H46R mSOD1 indicating a pathological
mechanism common to SALS and SOD1 FALS. In this
study, we searched for signs of SOD1 involvement in ALS
focusing on non-neuronal cells. The major novel ﬁnding is
that misfolded SOD1 is regularly present in the nuclei of
ventral horn astrocytes, microglia, and oligodendrocytes in
ALS patients carrying SOD1 mutations as well as in spo-
radic and familial patients lacking such mutations. Only
negligible staining was seen in control patients with neu-




Department of Neurology, Umea ˚ University Hospital. The
groupconsistedof43patientswithSALS[meanage68 ± 12
(17–88) years] and 8 patients with FALS without SOD1
mutations[meanage59 ± 11(39–71)years].Thenon-SOD1
FALS patients were subjected to genetic screening for
mutations in the following genes; transactivation-responsive
DNA-bindingproteinofmolecularweight43 kDa(TDP-43),
fusedinsarcoma(FUS),vesicleassociatedmembraneprotein
B (VAPB), angiogenin and optineurin, and none were found.
Moreover, nine ALS patients carrying SOD1 mutations were
included in the study: six patients homozygous for the D90A
mutation,twopatientsheterozygousfortheG127Xmutation,
and one patient heterozygous for the D101G mutation [mean
age 62 ± 11 (43–75) years]. ALS patients were diagnosed in
accordance with the revised criteria of El Escorial [6]. In
addition, two patients with spinobulbar muscular atrophy
(SBMA) (aged 52 and 76 years, respectively) were included
in the study.
Tissues were also collected from 26 control patients
with other neurodegenerative diseases [mean age 74 ± 19
(2–92) years; 12 with Alzheimer’s disease; six with Par-
kinson’s disease; three with multiple sclerosis, one with
tuberous sclerosis, one with Huntington’s disease, one with
spinocerebellar ataxia 7, one with autosomal dominant
progressive external ophthalmoplegia, and one with ar-
gyrophilic grain disease]. Tissues from 20 control patients
without neurological disease [mean age 69 ± 17 (37–91)
years; all patients died from heart conditions or pneumo-
nia) were also examined. The post-mortem time for all
patients was estimated to be between 0 and 3 days, and
there was no difference in postmortem time between the
groups. The study adhered to the tenets of the Helsinki
Declaration, and was approved by the Ethical Committee
of Umea ˚ University. For detailed information on subject
collection, see Electronic Supplementary Material.
Antibodies
For detection of misfolded SOD1, a set of polyclonal rabbit
(Ra) antibodies (ab) raised against keyhole limpet hemo-
cyanin-coupled peptides corresponding to amino acids 4–20
(Ra 4–20 ab), 57–72 (Ra 57–72 ab), and 131–153 (Ra
131–153 ab) in the human SOD1 sequence were used. A set
of polyclonal chicken (Chi) antibodies corresponding to the
same set of peptides was also used (Chi 4–20 ab, Chi 57–72
ab, Chi 131–153 ab, respectively). The antisera were
afﬁnity puriﬁed in two steps as described in previous papers
[12, 23]. G127X mutant SOD1 has following Gly-127 a 5
amino acid long neopeptide before the C-terminal trunca-
tion. CNS material from G127X mutant SOD1-carriers was
also stained with a mutant-speciﬁc Ra SOD1 peptide anti-
body directed against amino acids 123–132 in the mutant:
CADDLGGQRWK, (neopeptide shown in bold). This
antibody shows no reaction with wild-type human SOD1
[22]. Other commercially available antibodies used in the
study are presented in Online Resource, Table S1.
Immunohistochemistry
After blocking, sections were incubated with primary
antibodies and subsequently with corresponding ﬂuorescent
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123secondary antibodies or with biotin-conjugated secondary
antibodies coupled to an avidin-horseradish peroxidase
conjugate, and were visualized using aminoethylcarbazole
as the precipitating enzyme product.The primary antibodies
used were either the anti-SOD1 peptide antibodies descri-
bed above or the antibodies shown in Online Resource
Table S1. The sections were examined by confocal laser
microscopy or using an Olympus BX50 light microscope. A
four-tiered semi-quantitative scale was used to estimate the
number of glial cell nuclei in each cross-section of spinal
cord showing misfolded SOD1 staining. The levels were:
0 = no glial cells with nuclear staining; 1 =\25% of the
glial cells showing nuclear staining; 2 = 25–75% of the
glial cells showing nuclear staining; and 3 =[75% of the
glial cells showing nuclear staining. Sections from cervical,
thoracic, and lumbar spinal cord were analysed for each
patient and the result is presented in Table 1. Data for
proportion of glial cell nuclei with staining were calculated
as median (range). For detailed information on staining
methods, see Electronic Supplementary Material.
Results
Antibody characterization
We have developed a set of rabbit and chicken antibodies
against peptides in the human SOD1 sequence. The anti-
bodies show high speciﬁcities for SOD1 in western
immunoblots of human ventral horn extracts and they react
only with misfolded SOD1 species in immunocapture
experiments [12] (see also Online Resource, Fig. S1a, b). To
further ascertain their speciﬁcities for misfolded SOD1 in
immunohistochemical applications, the Ra 57–72 and the
Ra 131–153 antibodies, and the Chi 57–72 and 131–153
antibodies, respectively, were subjected to preincubations.
When pre-incubated with the appropriate immunizing
peptide or with denatured SOD1, complete blocking of the
signal was seen (Online Resource, Fig. S2b, d). Native
SOD1 had no blocking effect (Online Resource, Fig. S2c).
Exclusion of the primary antibodies resulted in the disap-
pearance of all immunostaining. These studies show that the
antibodies can be used for the speciﬁc detection of mis-
folded SOD1 species against the abundant background of
natively folded SOD1 in tissues. In the following, positive
immunohistochemical staining with these antibodies will be
referred to as misSOD1 staining.
Misfolded SOD1 is found in the nuclei of glial cells
in ALS patients carrying SOD1 mutations
Spinal cord sections from the nine ALS patients carrying
SOD1 mutations were stained with the anti-SOD1 peptide
antibodies. Aggregates/inclusions of misfolded SOD1 in
the soma, axons, and dendrites of affected motoneurons
were seen as previously described (Fig. 1d) [33, 36].
There was, however, also prominent staining of the nuclei
of glial cells (Figs. 1a, d, 2a). The staining was composed
of granules measuring 0.5–2 lm, which were dispersed
throughout the nuclei. The immunohistochemical ﬁndings
Table 1 MisSOD1 immunohistochemical results
Number of patients with nuclear misSOD1 staining in glial cells




Cervical spinal cord 8 (9) 6 (7) 39 (40) 2 (26) 1 (15)
Thoracic spinal cord 9 (9) 6 (7) 39 (39) 1 (2) 1 (18)
Lumbar spinal cord 9 (9) 5 (5) 32 (32) 2 (3) 1 (18)
Proportion of glial cells with nuclear misSOD1 staining




Cervical spinal cord 2 (1–3) 2 (0–3) 2 (0–3) 0 (0–2) 0 (0–2)
Thoracic spinal cord 2 (1–3) 3 (0–3) 2 (0–3) 0,2
a 0 (0–2)
Lumbar spinal cord 2 (1–3) 3 (2–3) 2 (1–3) 0,2,2
a 0 (0–2)
Table of ﬁndings from sections stained with the Ra 131–153 ab. Data for number of patients with nuclear staining in glial cells show the total
number of patients in parenthesis. Data for proportion of glial cell nuclei with staining are shown as median (range) referring to a four-tiered
semi-quantitative scale (0 = no glial cells with staining; 1 =\25% of the glial cells with staining; 2 = 25–75% of the glial cells showing
staining; 3 =[75% of the glial cells showing staining). The total number of patients in each group was as follows: SOD1 FALS, 9; non-SOD1
FALS, 8; SALS, 43; neurodegenerative controls, 26; non-neurological controls, 20. Sections from all levels were not available from all patients
a Since thoracic spinal cord only was available from two patients and lumbar spinal cord only from three patients from the neurodegenerative
control group, each result is presented individually
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123were identical using the different rabbit and chicken anti-
SOD1 peptide antibodies, and the intranuclear SOD1
positive granules in glial cells were seen at all levels of the
spinal cord and in both grey and adjacent white matter.
The staining was detected with both bright-ﬁeld and
immunoﬂuorescence microscopy (Figs 1a, 2a). Using a
four-tiered semi-quantitative scale to estimate the pro-
portion of glial nuclei with misSOD1 staining in one
section, all patients homozygous for the D90A mutation
showed misSOD1 staining in glial cell nuclei, ranging
from less than 25% in two patients and up to almost 100%
in four patients (Table 1). The D101G patient showed
misSOD1 staining in approximately 25% of the glial cell
nuclei (Table 1).
Both patients with the G127X mutation showed nuclear
staining of glial cells, but they differed in the proportion of
cells that stained. Using the G127X-speciﬁc Ra 123–132
ab, misSOD1 staining was seen in\25% of the glial cell
nuclei in both patients. One of the two patients also had
some nuclear staining in motoneurons. Interestingly, the
Chi 131–153 ab, raised against a peptide sequence that is
absent in the G127X mutant SOD1, gave rise to misSOD1
staining in glial cell nuclei in both G127X patients, and in
one of them it was seen in more than 75% of the glial cell
nuclei. Double staining with the Chi 131–153 ab and the
G127X mutant-speciﬁc ab mostly showed separate aggre-
gates of misSOD1 staining, without co-localization (Online
Resource, Fig. S3a–c). Performing double-staining with an
antibody that detect both misfolded wildtype and G127X
mutant SOD1 protein, the Chi 53–72 ab, with the mutant-
speciﬁc G127X ab yielded sometimes co-localization as in
large aggregates in motoneurons (Online Resource, Fig.
S3d–f) but also single staining with the Chi 57–72 ab as in
the arrow-head marked glial nucleus. This indicates that
Fig. 1 Misfolded superoxide dismutase-1 (misSOD1) is present in
spinal cord ventral horn of ALS patients. Immunohistochemistry was
performed with the Ra 131–153 ab in all cases. a Presence of
misSOD1 in glial cell nuclei of a FALS patient homozygous for the
D90A SOD1 mutation. b MisSOD1 in glial cell nuclei of a FALS
patient not linked to SOD1 mutations. c MisSOD1 in glial cell nuclei
of a SALS patient. A motoneuron also shows granular somal
inclusions. d Higher magniﬁcation of a motoneuron from a patient
homozygous for the D90A mutation, showing the presence of
misSOD1 in the nucleus (arrow) and widely spread in the soma.
Strongly stained glial nuclei are also seen. Motoneurons from a SALS
patient showing intranuclear staining (e) and somal staining (f)o f
misSOD1. Strongly stained glial nuclei are also present in the section.
g MisSOD1 in glial cell nuclei (arrows) and in motor neuron nuclei
(arrowhead) from a patient with FALS not linked to SOD1 mutations.
h Four of 46 control patients showed weak misSOD1-staining in
spinal cord glial cell nuclei. As an example, the ﬁgure shows a non-
neurological control patient. i Material from a control patient with
Alzheimer’s disease showing no evidence of misSOD1. Scale bars are
50 lm( a, b), 30 lm( c, d), 20 lm( e, f)o r5 0lm( g, h, i)
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123some of the misSOD1 staining within the glial cell nuclei
of G127X patients has originated from wild-type SOD1.
To establish that the misSOD1 staining observed was
present inside neuronal and glial nuclei, double immuno-
ﬂuorescence staining with an antibody to the structural
nucleoporin protein NUP 62, which localizes to the
nucleoplasmic region of the nuclear envelope, was per-
formed [29]. Double staining with the NUP 62 antibody
revealed the nuclear envelope, and inside it misSOD1
staining was seen (Online Resource, Fig. S4). MisSOD1
staining can thus be intranuclear in motoneurons and is
principally intranuclear in glial cells.
Misfolded SOD1 is regularly found in the nuclei of glial
cells and occasionally in motoneuron nuclei of ALS
patients lacking SOD1 mutations
Sectionsofspinalcordfrom43patientswithSALSandfrom
8 patients with FALS, all of whom lacked SOD1 mutations,
as well as 2 patients with SBMA, were stained with the
antibodies to SOD1 peptides. Intranuclear staining in glial
cells was seen both in the SALS and the FALS patients. The
staining patterns were virtually identical to those seen in the
patients carrying SOD1 mutations. All sporadic ALS
patients showed misSOD1 staining in their glial nuclei
(Figs. 1c,e,2b,3a,d,g,4aandOnlineResource,Fig.S4f),as
did seven of the eight FALS patients who lacked SOD1
mutations (Figs. 1b, 2c, 4d). We were unable to ﬁnd nuclear
misSOD1 staining in one FALS patient. On average, the
proportion of glial cells in each section with misSOD1
staining was close to 75%, and ranged from\25% in some
patients up to 100% in others (Table 1). The intranuclear
SOD1 positive granules in glial cells were primarily seen in
the ventral horn and adjacent white matter but some could
also be observed in the dorsal horn and the dorso-medial
white matter. Overall, the nuclear misSOD1 staining in glial
cells was at least as prominent in patients lacking SOD1
mutations as in patients carrying such mutations (Table 1).
IntranuclearstainingforSOD1inglialcellswasalsopresent
in the two SBMA patients included in the study.
Small and numerous aggregates of misfolded SOD1were
seen in the cytoplasm of motoneurons from ALS patients
Fig. 2 MisSOD1 staining is seen in human spinal cord ventral horn
motoneurons and glial cells of ALS patients. All sections were stained
with the Ra 57–72 ab. Presence of misSOD1 in glial cell nuclei
(arrowheads) in a familial ALS (FALS) patient with the G127X
SOD1 mutation (a), in a sporadic ALS (SALS) patient (b), and in a
FALS patient not linked to SOD1 mutation (c). Higher magniﬁcation
of different misSOD1 staining patterns in motoneurons from two
SALS cases. The nuclear staining appears as granular aggregates
approximately 0.5–3 lm in size, often seen in association with the
nucleolus (d). In motoneurons with nuclear staining, the cytoplasm
appears to contain less of the small misSOD1 inclusions. In panels
b and e, misSOD1 aggregates can be seen scattered throughout the
cytoplasm of motoneurons, and are particularly abundant in the somal
area, while not penetrating the nuclear envelope (arrows). f MisSOD1
staining in a sample from a neurodegenerative control patient with
Alzheimer’s disease. Glial cell nuclei and motoneurons lack mis-
SOD1 aggregates/inclusions. Scale bars are 40 lm( a, b), 50 lm( c),
20 lm( d, e)o r3 0lm( f)
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123lacking mutations in the SOD1 gene, as we have previously
reported [12]. These misfolded SOD1 aggregates were
often scattered throughout the cytoplasm and were partic-
ularly abundant in the perinuclear area, but did not penetrate
the nuclear envelope (Figs. 1f, 2b, e, 4d) [12]. However,
occasionally motoneurons also showed nuclear misSOD1
staining. The staining then appeared as nuclear aggregates
approximately 0.5–3 lm in size, often in association with
the nucleolus (Figs. 1e, g, 2d and Online Resource, Fig.
S4a). In motoneurons with nuclear staining, the cytoplasm
often appeared to contain fewer aggregates of misfolded
SOD1 (Fig. 1e). The motoneurons thus showed two types of
misSOD1 staining: either intranuclear staining in moto-
neurons or a perinuclear misSOD1 staining with numerous
aggregates of misfolded SOD1 in the soma but no sign of
intranuclear staining (Fig. 2e). In the latter case, the nucleus
appeared to be spared, leaving the impression that the
nuclear envelope was acting as a barrier. The two types of
motoneuron staining appeared to co-exist in the ventral
horns and they could be seen in the same section, although
Fig. 3 Aggregates of misfolded SOD1 are found in astrocytes,
microglia and oligodendrocytes. Micrographs of lumbar ventral horn
glial cells from two SALS patients (a–c and g–i) and a FALS patient
homozygous for the D90A mutation (d–f) labeled with the Chi
131–153 ab (a, g) and the Ra 131–153 ab (d). (a–c) Double
immunoﬂuorescence labeling showing misSOD1 (green) and the
astrocyte marker GFAP (red). In panel c, most of the glial cell nuclei
containing misSOD1 are astrocytes. d–f Double immunoﬂuorescence
labeling showing misSOD1 (green) and the microglial marker Iba1
(red). In panel f, some of the glial cells with nuclear misSOD1
staining are microglia. g–i Double immunoﬂuorescence labeling
showing misSOD1 (green) and the oligodendroglial marker Olig 2
(red). In panel i, misSOD1 is present in the nuclei of oligodendro-
cytes. Scale bars are 20 lm( a–c) and 10 lm( d–i)
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123somal and perinuclear staining was more common and was
seen in all ALS patients investigated. On the other hand, the
intranuclear staining in motoneurons was seen in 30 of 43
SALS patients and in six of eight FALS patients, all of
whom lacked SOD1 mutations. Four out of the six patients
homozygous for the D90A mutation and one of the two
SBMA patients showed inclusions of misfolded SOD1 in
the nuclei of motoneurons. The nuclear staining was only
seen in a few motoneurons per section, and not in all sec-
tions investigated.
Nuclear staining of SOD1 in glial cells was speciﬁc
for tissues affected by ALS and was not seen in controls
with non-neurological or other neurodegenerative
diseases
Spinal cord sections from 20 patients who died of non-
neurological diseases were stained with the anti-SOD1
peptide antibodies. Only one patient showed misSOD1
staining in the nucleus of glial cells and motoneurons
(Fig. 1h). The proportion of staining was \25% in that
patient, and staining was not seen in all sections investi-
gated (Table 1). Twenty-six controls with other
neurodegenerative diseases were also examined. Twenty-
three of these controls did not stain for misfolded SOD1 in
ventral horn glial cell nuclei; nor was misfolded SOD1
detected in the nuclei of motoneurons (Figs. 1i, 2f). As the
spinal cord is not the primary site of pathology in other
neurodegenerative diseases, we also examined the brain
areas mainly affected in Alzheimer’s disease, Huntington’s
disease, and Parkinson’s disease. We could not detect any
misfolded SOD1 immunoreactivity in areas of the hippo-
campus, temporal, and frontal cortex, putamen, striatum,
and substantia nigra (data not shown). The 4 of 46 controls
that stained positive for misSOD1 showed increased GFAP
staining in the spinal cord. All four also showed cyto-
plasmic inclusions in motoneurons when stained with
ubiquitin, and in one neurodegenerative control, a patient
with Alzheimer’s disease, a few skein inclusions could be
seen in the motoneuronal cytoplasm as well.
Fig. 4 Aggregates of misfolded SOD1 in glial cell nuclei occasion-
ally co-localize with ubiquitin, but not with TDP-43. Micrographs of
cervical and lumbar spinal cord ventral horn sections from a SALS
patient stained with the Chi 57–72 ab for misSOD1 (green) and with
antibodies to ubiquitin and TDP-43 (red). MisSOD1 could be seen in
glial cell nuclei (a) and in the cytoplasm of a motoneuron (d).
Staining with the anti-ubiquitin antibody showed that some glial cell
nuclei contained ubiquitin (b, arrows) and the merged picture
(c) revealed some co-localization of ubiquitin and misSOD1 (arrows),
although misSOD1 could also be seen separate from ubiquitin
(arrowheads). Staining with anti-TDP-43 antibody revealed that some
glial nuclei contained TDP-43 (e, arrows). Occasionally, misSOD1
and TDP-43 were present in the same glial cell nuclei (f) but no
distinct co-localization of misSOD1 and TDP-43 was apparent. Scale
bars are 20 lm( a–f)
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123Misfolded SOD1 is also found motoneurons and glial
cells in brainstem and motor cortex
Mid-olivary sections from the brainstem from 12 neuro-
degenerative control patients, from 11 SALS patients, 2
non-SOD1 FALS patients and 8 SOD1 mutated patients
were investigated for misfolded SOD1 by immunohisto-
chemistry. In brain stem motor nuclei, we found
intranuclear misSOD1 staining in glial cells in all ALS
patients, although the number varied between patients.
Staining was generally found in fewer glial cells than seen
in the spinal cord. The staining was mainly found in motor
nuclei and in the inferior olivary nucleus. We also found a
primarily cytoplasmic staining in brain stem motoneurons
in all ALS patients, while nuclear staining was only
occasionally observed. We found no staining in the control
patients investigated.
Sections from motor cortex were investigated in eight
SALS patients. All patients had misSOD1 staining in glial
cell nuclei and some cytoplasmic staining in neurons. The
staining was less than found in brainstem and spinal cord.
Identiﬁcation of glial cell types with nuclear staining
of misfolded SOD1
Next, we wanted to identify the glial cell types carrying
nuclei that were positive for misfolded SOD1. We used
double-labeling immunoﬂuorescence with the anti-SOD1
peptide antibodies and antibody markers for astrocytes,
microglia, and oligodendrocytes. Using confocal laser
scanning microscopy, we could show that most of the
nuclei carrying misSOD1 staining were present in cells
positive for the astrocytic marker GFAP (Fig. 3a–c).
Double-labeled astrocytes were seen both in white and grey
matter, and they were seen in all cases where positive
staining for misfolded SOD1 was seen. We also found that
some of the nuclei that were positive for misfolded SOD1
were present in cells that expressed the microglial marker
Iba1 (Fig. 3d–f), although not all microglia had misfolded
SOD1 in the nucleus. In addition, a few of the glial cell
nuclei that stained for misfolded SOD1 expressed the olig 2
marker (Fig. 3g–i). These double-labeled oligodendroglia
nuclei were much smaller and occurred less frequently than
the astrocyte nuclei in the sections investigated.
SOD1-positive inclusions in glial cell nuclei
occasionally co-localized with ubiquitin,
but not with TDP-43 or p62
In the samples from SALS and FALS patients lacking
SOD1 mutations stained with an antibody directed against
TDP-43, cytoplasmic inclusions in motoneurons were seen
in all sections investigated, as skein-like and/or ﬁne
granular punctuate inclusions, in accordance with the pre-
vious reports [1, 31]. For a more detailed description, see
Electronic Supplementary Material. When ALS patients
lacking SOD1 mutations were double-stained with the anti-
SOD1 peptide antibodies, TDP-43 was not found to co-
localize with the misfolded SOD1 aggregates seen in the
somas of motoneurons. Occasionally, misfolded SOD1 and
TDP-43 were located in the same glial or motoneuron
nucleus but no co-localization could be demonstrated
(Fig. 4d–f). Interestingly, two control patients, one with
Alzheimer’s disease and another with cardiovascular dis-
ease, had TDP-43 positive neuronal cytoplasmic inclusions
in the shape of skein inclusions in the cytoplasm of spinal
cord motoneurons (data not shown). The staining was not
different from that seen in SALS patients. Both of these
controls were negative when staining for misfolded SOD1.
The two SBMA patients also showed cytosolic TDP-43
staining typical of SALS patients (data not shown).
Since misfolded proteins present in the nuclei are
degraded through the ubiquitin–proteasome pathway, we
performed double immunoﬂuorescence staining for mis-
folded SOD1 and ubiquitin. Occasionally, misfolded SOD1
co-localized with ubiquitin in glial cell nuclei, although
most misSOD1 staining in glial cell nuclei was ubiquitin-
negative (Fig. 4a–c).
The polyubiquitin-binding protein p62 (sequestosome 1)
has been proposed to act as a factor for shuttling of poly-
ubiquitinated proteins to the proteasome for degradation
[38], and it has also been reported to interact with mutant
SOD1 in cultured cells [14]. Using two anti-p62 antibodies,
staining of sections from ALS patients and controls failed
to show any nuclear immunoreactivity in glial cells and
motoneurons (data not shown). However, all ALS patients
and 8 of the 47 controls had p62 staining in the cytoplasm,
in the shape of punctuate and skein-like inclusions, as has
been described before [32]. The cytoplasmic p62 aggre-
gates showed co-localization when double-labeling was
performed with ubiquitin, but no co-localization of mis-
folded SOD1 and p62 was seen (Online Resource, Fig. S5).
Discussion
The main new ﬁnding in this study is that misfolded SOD1
is present as small aggregates in the nuclei of glial cells of
spinal cord tissue from ALS patients. These aggregates
were found in ALS patients carrying SOD1 mutations as
well as in sporadic and familial ALS patients lacking such
mutations. Nuclear staining of misfolded SOD1 in glial
cells was found in 59 of 60 ALS patients investigated. Only
4 of the 46 non-neurological and neurodegenerative con-
trols had misSOD1 staining, but it was sparse and not seen
at all levels of the spinal cord (Table 1). Since the vast
630 Acta Neuropathol (2011) 121:623–634
123majority of control cases lacked staining, the misSOD1
staining seen in ALS cases is unlikely to represent post-
mortem changes, which strongly suggests that the ﬁnding
was related to ALS pathology. The glial cells containing
misfolded SOD1 in the nucleus were mostly astrocytes but
some microglial and oligodendroglial nuclei also stained
positive for misfolded SOD1 (Fig. 3). Misfolded SOD1
was occasionally found in the nuclei of motoneurons.
Many histopathological studies which included staining
for SOD1, have been carried out before on ventral horns
from ALS patients with and without SOD1 mutations. It
could appear curious that the glial nuclear staining not has
been observed before. The likely explanation is that in
most cases antibodies raised against whole human SOD1
have been used. Such antibodies react avidly with both
native and denatured SOD1 [12], and the minute amounts
of misfolded SOD1 will thus be masked by the staining of
the abundant native SOD1 in the cells. Other studies using
monoclonal conformation-speciﬁc antibodies directed
towards peptides in the SOD1dimer interface or in the
unfolded beta-barrel have failed to show misSOD1 staining
in patients with sporadic disease or non-SOD1 mediated
FALS [28, 30]. A possible explanation for this could be
that SOD1 in sporadic disease might have different mis-
folded conformation/-s compared to SOD1-mediated
disease. Monoclonal peptide antibodies with only one
speciﬁc antigen determinant might fail to detect other
misfolded conformations, whereas polyclonal antibodies
with several speciﬁc antigenic determinants could detect
different misfolded conﬁrmations. Finally, the antigen
retrieval could have differed. If it is too strongly denatur-
ing, extensive misfolding of the background native SOD1
might occur, hampering detection of the misfolded SOD1
present in the tissue.
Our ﬁnding that misfolded SOD1 is present in glial cell
nuclei of FALS patients carrying SOD1 mutations as well
as in ALS patients lacking such mutations support the
notion of a pathological interplay between neurons and
glial cells. It raises the question of how these non-moto-
neuron abnormalities might contribute to motoneuron
degeneration and disease progression. Studies using trans-
genic ALS mice have shown aggregates of mutant SOD1 in
astrocytes, microglia, and oligodendrocytes [7, 17, 20].
Regarding studies on human post-mortem tissue, cytosolic
inclusions in spinal cord astrocytes, intensely stained with
an antibody to SOD1, have been observed in two long-term
surviving FALS patients carrying SOD1 mutations [27]. In
the present study, all nine FALS patients carrying SOD1
mutations had staining of mutant SOD1 in glial cells,
although the staining of misfolded SOD1 was primarily
seen in the nuclei.
When using the mutant-speciﬁc G127X Ra 123–132
SOD1 ab, approximately 25% of the glial cell nuclei in
both FALS patients with the G127X SOD1 mutant were
stained, whereas using the Chi 131–153 ab, (raised to a
peptide sequence that is absent in the G127X-mutated
SOD1 protein) also gave staining of misfolded SOD1 in
glial cell nuclei in the G127X patients. Performing double-
staining with the two antibodies yielded mostly separate
aggregates of misSOD1 staining and no co-localization was
seen (Online Resource, Fig. S3a–c). This indicates that
misfolded wild-type SOD1 protein may participate in the
disease process even in patients carrying mutations.
Wild-type native SOD1 is normally located in the
cytosol, the intermembrane space of mitochondria, and in
the nucleus [44]. Bidirectional movement of small proteins
occurs via passive diffusion through the nuclear pore
complex, whereas proteins larger than about 40 kDa gen-
erally require speciﬁc transportation [41]. The size of the
native SOD1 dimer is 32 kDa, and it should, therefore, be
able to move freely between the nucleus and the cytosol.
Accordingly, Chang et al. [8] found the native SOD1
concentration in the nucleus to be at least half that in the
cytoplasm. In transgenic ALS models carrying mutant
human SOD1s, misfolded SOD1 lacking the stabilizing
intrasubunit C57-C146 disulﬁde bond is enriched in the
susceptible spinal cord [48]. Such disulﬁde-reduced SOD1
readily forms aggregates in vitro [9, 13] and is the major
component of SOD1 aggregates present in symptomatic
transgenic mice [3, 26]. Misfolded disulﬁde-reduced SOD1
is consequently a likely source of the aggregates/inclusions
of SOD1 observed in the present study. In glial cells, the
aggregation mainly appears to take place in the nuclei
whereas in neurons it is more prominent in the soma.
Unlike dimeric and monomeric SOD1, aggregated SOD1
will be trapped and potentially accumulated in the nuclei. It
is possible that both the nucleus and the cytoplasm contain
targets that are vulnerable to misfolded SOD1, but that the
cytoplasm of glial cells may be better equipped to neu-
tralize or degrade the proteotoxic agent. Autophagy is the
major mechanism for degradation of aggregates [18, 37]
and the absence of this process in nuclei might contribute
to the staining pattern of misfolded SOD1 observed. There
is no evidence for extensive glial cell death in ALS. This
suggests that any harmful effects of the misfolded SOD1
would not lead to glial death, but rather to activation
causing damage to motoneurons. Whether the nuclear
aggregates are cytotoxic, or merely terminal markers of
toxic soluble misfolded disulﬁde-reduced SOD1 (or both
species essentially innocent) can only be speculated on at
present. Misfolded SOD1 may be toxic by exposing
internal structures that interact with essential nuclear fac-
tors, or it may aggregate with such factors, or (as
aggregates) it may physically block processes in the nuclei.
Mutant SOD1 has been reported to have both RNA [15]
and DNA-binding capacity [21], indicating the possibility
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123of direct interaction with polynucleotides. In this context, it
is interesting to note that several proteins found to be
mutated in motor neuron diseases, such as TDP-43, FUS,
angiogenin, and senataxin, can inﬂuence gene transcription
and RNA turnover [40]. More details on TDP-43 and
SOD1 are reported in Electronic Supplementary Material.
In neurodegenerative conditions, such as Alzheimer’s
and Parkinson’s diseases, proteins found to be mutated in
some familial patients (amyloid precursor protein/b-amy-
loid, a-synuclein) are generally assumed to be key players
in the pathogenesis in sporadic patients. Immunohisto-
chemical results constitute the strongest evidence for these
suppositions. Here we have shown that inclusions of the
misfolded SOD1 are regularly present in glial nuclei, both
in ALS patients carrying SOD1 mutations and in sporadic
and familial cases lacking such mutations. The ﬁnding
expands on the previous demonstration of SOD1 inclusions
in the soma of motoneurons in ALS patients lacking SOD1
mutations [5, 12]. Together, these studies suggest that
misfolded SOD1 is generally involved in the pathogenesis
of ALS.
As with SOD1, mutations in two other proteins, TDP-43
and FUS, have been found to cause ALS with a phenotype
spectrum similar to that seen in sporadic disease. Inclusions
containing TDP-43 are found in the soma of motoneurons
both in carriers of TDP-43 mutations and in sporadic
patients [25, 39] but not in carriers of SOD1 mutations [31]
and FUS mutations [42]. Based on this discrepancy, it has
been suggested that the pathogenesis of ALS caused by
mutant SOD1s is different from that in sporadic ALS and
ALS provoked by TDP-43 mutations. Our present ﬁndings
and the ﬁndings of Bosco et al. [5] contradict this propo-
sition even though no details on TDP-43 or FUS were
provided in the latter study. Regarding involvement of the
proteins found mutated in FALS pedigrees in sporadic
ALS, these proteins possibly occupy different steps or
occur in parallel routes in pathogenic chains of events. The
fact that intranuclear glial and motoneuron inclusions were
seen in the two SBMA patients as well as in the familial
non-SOD1 patients suggests that SOD1 might be involved
in downstream events even in motoneuron disease induced
by mutations in other genes [12].
In summary, our observation that misfolded SOD1 is
present in the nucleus of motoneurons and astrocytes also
implicates the nucleus as a potential site of SOD1 toxicity.
More studies are needed to clarify the distribution of
misfolded SOD1 in non-neuronal cells and to explore in
more detail the modes of SOD1 toxicity at different sites.
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